NCT04919096View on ClinicalTrials.gov

Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

January 31, 2023

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

SCB-420

Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.

DRUG

Aflibercept

Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY